Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) announced preliminary, unaudited net sales for Q4 and the full year ending December 31, 2020. Q4 net sales are estimated at $73 million, with $58 million from Glaucoma and $15 million from Corneal Health. For the full year, net sales are projected at $225 million, driven by $179 million in Glaucoma and $46 million in Corneal Health. CEO Thomas Burns acknowledged the team's efforts amidst COVID-19 challenges and expressed confidence in the company's future, although caution remains due to ongoing uncertainties. Final results will be available in late February.
Glaukos Corporation (NYSE: GKOS) announced its management will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:00 a.m. PST. Investors can access a live and archived webcast on the company's website. Glaukos focuses on innovative therapies for glaucoma and other ophthalmic conditions, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its iStent® devices launched since 2012. The company's technology aims to transform glaucoma treatment and enhance corneal health through specialized pharmaceuticals and surgical therapies.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its participation in upcoming investor conferences. These include the Berenberg U.S. CEO Conference on November 12, 2020, the Stephens Annual Investment Conference on November 19, 2020, and the Piper Sandler 32nd Annual Healthcare Conference with events on November 23 and December 2, 2020. Live webcasts of these events will be accessible on Glaukos' investor website. Glaukos focuses on innovative therapies for glaucoma and corneal disorders, pioneering Micro-Invasive Glaucoma Surgery.
Glaukos Corporation (NYSE: GKOS) reported Q3 2020 net sales of $64.8 million, an increase from $58.5 million in Q3 2019. Glaucoma net sales reached $51.9 million, while Corneal Health net sales were $12.9 million. The gross margin stood at approximately 72%, down from 87% in Q3 2019. Operating expenses totaled $59.3 million, with a net loss of $15.7 million or ($0.35) per share. Glaukos has withdrawn its 2020 revenue guidance due to uncertainties from the COVID-19 impact.
Glaukos Corporation (NYSE: GKOS) will release its third quarter 2020 financial results on November 5, 2020, after market close. Management will discuss the results during a conference call at 1:30 p.m. PST (4:30 p.m. EST) on the same day. Interested parties can access the live webcast via the company’s website. Glaukos focuses on innovative technologies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with products like the iStent.